If you have been reading about adipose tissue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
=== Pharmacokinetics === When administered orally in a 70:30 molar ratio, serdexmethylphenidate/dexmethylphenidate produces a dexmethylphenidate plasma concentration profile with a time to maximum concentration Tmax of approximately 2 hours and an mean terminal elimination half-life of 11.7 hours.
Absorption of cadmium through the lungs is more effective than through the gut. As much as 50% of the cadmium inhaled in cigarette smoke may be absorbed. On average, cadmium concentrations in the blood of smokers is 4 to 5 times greater than non-smokers and in the kidney, 2–3 times greater than in non-smokers. Despite the high cadmium content in cigarette smoke, there seems to be little exposure to cadmium from passive smoking. In a non-smoking population, food accounts for around 90% of cadmium uptake. High quantities of cadmium can be found in crustaceans, mollusks, offal, frog legs, cocoa powder, bitter and semi-bitter chocolate, seaweed, fungi and algae products. However, grains, vegetables, and starchy roots and tubers are consumed in much greater quantity in the U.S., and are the source of the greatest dietary exposure there. Most plants bio-accumulate metal toxins such as cadmium and when composted to form organic fertilizers, yield a product that often can contain high amounts (e.g., over 0.5 mg) of metal toxins for every kilogram of fertilizer. Fertilizers made from animal dung (e.g., cow dung) or urban waste can contain similar amounts of cadmium. The cadmium added to the soil from fertilizers (rock phosphates or organic fertilizers) become bio-available and toxic only if the soil pH is low (i.e., acidic soils). In the European Union, an analysis of almost 22,000 topsoil samples with LUCAS survey concluded that 5.5% of samples have concentrations higher than 1 mg kg−1.
Adnexal mass entry in the public domain NCI Dictionary of Cancer Terms Emedicine overview This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
Sources: en.wikipedia.org
{\displaystyle p\left(r\right)={\frac {Ed}{\pi a\left(1-\nu ^{2}\right)}}\ln \left({\frac {a}{r}}+{\sqrt {\left({\frac {a}{r}}\right)^{2}-1}}\right)={\frac {Ed}{\pi a\left(1-\nu ^{2}\right)}}\cosh ^{-1}\left({\frac {a}{r}}\right)}
=== Launch === At 8:04:13 a.m. EST, May 15, 1963, Faith 7 was launched from Launch Complex 14. At T+60 seconds, the Atlas started its pitch program. Shortly afterward, MA-9 passed through max Q. At T+2 minutes 14 seconds Cooper felt BECO (Booster Engine Cutoff) and staging. The two Atlas booster engines had been left behind. The Launch Escape Tower was then jettisoned. At T+3 minutes the cabin pressure sealed at 5.5 psi (38 kPa). Cooper reported, "Faith 7 is all go."
Insulin-degrading enzyme (IDE) (also known as insulinase, insulin protease, or insulysin) is a large zinc-binding protease of the M16 metalloprotease family of enzymes. It is known to cleave multiple short polypeptides that vary considerably in sequence, including insulin. Other members of this family include the mitochondrial processing peptidase and presequence protease. Insulin-degrading enzyme is coded for in the human by the IDE gene.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.